Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Phase II Trial of Ibrutinib Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma

NCT02744612 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT02744612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02744612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Phase II Trial of Ibrutinib Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Completed
Start date
June 20, 2016
Completion date
July 30, 2024
Enrollment
39 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent hodgkin lymphoma, refractory hodgkin lymphoma